β-羟基异戊酰紫草素二甲醚衍生物对白血病细胞株THP-1的作用

目的 选用人类单核细胞白血病细胞株THP-1,体外加入紫草素二甲醚衍生物5,8-二甲基-2-β-羟基异戊酰紫草素(SK36),研究其在THP-1细胞株增殖和凋亡中的作用,并对其作用机制进行初步探讨.方法 CCK法检测SK36对THP-1细胞的增殖抑制作用;流式细胞术检测细胞早期凋亡标记Annexin V/PI及细胞凋亡通路Caspase活性;激光共聚焦显微镜观察细胞凋亡和坏死.结果 流式细胞术检测结果显示,1.02μg/ml SK36作用24、48 h后的细胞凋亡率分别为(40.61±2.13)%和(67.40 ±9.15)%,明显高于对照组的(16.97±0.61)%,差异有统计学意义(t=18.444,t=9.528,P<0.01);SK36诱导THP-1细胞凋亡且经历了Caspase-3的激活(F=323.61,P<0.01).结论 紫草素二甲醚衍生物SK36能有效地诱导THP-1细胞凋亡,其作用机制主要是激活Caspase-3.     

NF-κB信号通路的阻断对皮肤鳞癌SCL-1细胞凋亡的影响

目的:利用siRNA技术抑制核因子-kappa B(nuclear factor-kappa B,NF-κB)亚单位p65基因的表达,研究其对p65表达的抑制作用,并探讨其对皮肤鳞癌SCL-1细胞凋亡的影响.方法:将终浓度为50 nmol/L的p65 siR-NA转染皮肤鳞癌SCL-1细胞,通过RT-PCR检测p65 mRNA的表达;利用Western blotting检测p65、bcl-2和bax蛋白表达,利用Caspase-Glo(R)-3/7,8和9检测试剂盒检测caspase-3/9的活性;最后通过流式细胞术检测细胞凋亡.结果:p65 siRNA转染SCL-1细胞后的48 h,p65 mRNA的表达水平最低,与0 h相比,差异有统计学意义(0.23±0.10vs.0.66±0.05,P＜0.05);转染48 h后,p65和bcl-2蛋白表达水平下调,而促凋亡蛋白bax的表达上升,进一步caspase-3/9的活性也显著升高.流式细胞术结果表明,p65 siRNA能明显诱导SCL-1细胞发生凋亡,其早期凋亡的比率为20.28%±1.87%,显著高于未处理组和对照siRNA组(凋亡率分别为9.13%±1.51%和9.37%±1.38%,F=47.532,P＜0.01).结论:p65 siRNA能够阻断皮肤鳞癌细胞中NF-κB信号通路,并下调抑凋亡蛋白bcl-2的表达,上调促凋亡蛋白bax的表达以及提高caspase的活性,提示NF-κB信号通路有望成为皮肤鳞癌基因治疗的分子靶点.     

低剂量地西他滨联合伊马替尼对K562细胞的增殖抑制作用

目的 研究低剂量地西他滨(DAC)联合伊马替尼(IM)对K562细胞株的增殖抑制作用及对bcr-abl表达的影响.方法 单药及两药联合后,通过四甲基偶氮唑蓝(MTT)法观察药物对K562细胞株的增殖抑制作用,流式细胞术检测药物对K562细胞株早期凋亡率及细胞周期,巢式反转录-聚合酶链反应(RT-PCR)半定量检测药物对K562细胞株bcr-abl mRNA表达.结果 DAC与IM单药对K562细胞的抑制作用呈浓度时间依赖性.两药联合用药抑制作用较单药组明显(F=43.947、165.580、321.193、296.101,均P<0.05),24、48、72 h各浓度组与对照组比较差异均有统计学意义(F=202.759、168.457、417.538,均P<0.05).DAC及IM单药作用药物对K562细胞株均使G,期细胞明显增多,IM0.2μmol/L作用于K562细胞株48 h可见6.7%早期凋亡细胞,IM 0.2 μmol/L联合DAC 4μmol/L早期凋亡细胞增加至8.4%.bcr-abl mRNA表达水平降低,DAC 4 μmol/L作用48 h后可降低K562细胞中bcr-abl mRNA表达(约14%),IM 0.2 μmol/L降低约40%,联合用药表达量明显降低(约60%).联合用药组与单药组比较差异有统计学意义(F=71.981,P<0.05).结论 DAC对K562细胞的增殖抑制作用与细胞周期阻滞、诱导凋亡及降低bcr-abl mRNA表达有关,两药联合可显著抑制K562细胞增殖.     

白藜芦醇诱导白血病Molt-4细胞凋亡及对WAVE1基因表达的影响

目的 探讨白藜芦醇诱导人类急性淋巴细胞白血病Molt-4细胞凋亡的作用机制.方法 噻唑蓝比色法(MTF)测定细胞生长抑制率;流式细胞术检测细胞周期分布及凋亡率;半定量反转录聚合酶链反应(RT-PCR)法检测WAVE1基因的表达.结果 MTT结果显示:12.5、25.0、50.0、100.0、200.0 μmol/L的白藜芦醇作用于Moh-4细胞24、48、72 h后,细胞的最大抑制率分别达到29.32%、36.11%、53.92%、62.50%、74.98%,并呈时间-剂量依赖性(F=33.614,P<0.05);流式细胞术检测结果显示:与对照组相比,50.0、100.0 μmol/L白藜芦醇作用于Molt-4细胞48 h后,S期细胞比例由42.2%分别上升为68.6%和78.1%,细胞发生了S期阻滞(F=19.453,P<0.01);PCR结果显示:50.0、100.0 μmol/L的白藜芦醇处理Molt-4细胞48 h后,WAVE1/GAPDH比值分别为0.356±0.03、0.382±0.05,与对照组(0.586±0.06)比较,差异有统计学意义(F=8.950,P<0.01).结论 白藜芦醇可诱导Moh-4细胞发生凋亡,其作用机制可能与下调WAVE1基因表达有关.     

辛伐他汀联合阿糖胞苷对K562细胞增殖与凋亡的影响

目的 探讨辛伐他汀(SV)联合阿糖胞苷(Ara-C)对K562细胞增殖与凋亡的影响.方法 不同浓度SV和Ara-C单用或者联合处理K562细胞,对照组为K562细胞.药物作用24、48、72 h后收集细胞,分别观察各组细胞形态,采用MTT法检测不同组别细胞的生长抑制率,采用流式细胞术检测细胞早期凋亡率、细胞坏死比例.结果 SV联合Ara-C组与单药组相比细胞形态明显有核固缩现象,且可见凋亡小体形成,并且随着处理时间的增加,抑制率也增大.其中15 μmol/L SV联合20 μmol/LAra-C的细胞抑制作用最为显著,72 h细胞抑制率为(72±1)%,明显高于15 μmol/L SV组的(45±2)%和20μmol/LAra-C组的(44±0)%(P＜0.01),表现为协同抑制作用(24、48 h金氏Q值为1.24和1.19).流式细胞术检测发现20、15和10μmol/LSV组K562细胞早期凋亡率AnnexinV明显高于对照K562细胞(P＜0.01),而且随着时间延长和剂量的增大早期凋亡率也增加(P＜0.05).20和15 μmol/LSV组早期凋亡率均高于10 μmol/LSV组,而前两者之间差异无统计学意义(P＞0.05).晚期凋亡细胞率(PI)各组中差异均无统计学意义(P＞0.05).结论 SV体外抑制K562细胞增殖及诱导细胞凋亡,SV与Ara-C具有协同作用,增加了K562细胞对化疗药物的敏感性.15 μmol/L可能为SV体外最佳作用浓度.     

地西他滨联合三氧化二砷对NB4细胞凋亡作用的研究

目的 研究去甲基化制剂地西他滨(DAC)单用或联合三氧化二砷(As2O3)对NB4细胞凋亡的作用机制.方法 将不同浓度的DAC、As2O3以及两药联合作用于NB4细胞,不加药为对照组,采用四甲基偶氮唑蓝(MTT)法检测细胞增殖抑制作用,流式细胞术检测细胞凋亡.结果 DAC与As2O3单药对NB4细胞的抑制作用呈浓度时间依赖性(DAC 1 μmol/L作用24、48、72 h的抑制率分别为12.18%、22.72%、35.54%;DAC 2 μmol/L作用24、48、72 h的抑制率分别增高为22.14%、31.18%、45.21%;As2O3 0.5 μmol/L作用24、48、72 h的抑制率分别21.09%、32.43%、44.93%;As2O3 1.0 μmol/L作用24、48、72 h的抑制率分别增高为31.69%、41.12%及54.27%),两药联合抑制作用较单药明显(DAC 1 μmol/L+As2O3 0.5 μmol/L作用24、48、72 h抑制率分别为42.10%、48.75%、60.78%)(P<0.05),各浓度组与对照组比较差异均有统计学意义(P值均<0.05);As2O3 1 μmol/L作用于NB4细胞株48 h可见5.8%的细胞凋亡,联合组增高为17.3%.结论 DAC能显著抑制NB4细胞的增殖并诱导其凋亡,DAC联合As2O3对NB4细胞增殖抑制及诱导凋亡有协同作用.     

纳米SiO2颗粒在HepG2细胞中的分布及其细胞毒性

目的:检测纳米SiO2颗粒作用于HepG2细胞后纳米颗粒的细胞摄取、分布情况及颗粒对细胞的毒性作用,初步探讨纳米颗粒的摄取、分布与细胞毒性的关系.方法:采用透射电镜(TEM)及动态光散射法检测纳米SiO2颗粒的表征;纳米SiO2颗粒作用HepG2细胞后,用荧光显微镜及TEM观察纳米SiO2颗粒的细胞摄取及细胞内分布情况;不同浓度纳米SiO2颗粒(0、25、50、100 及200 mg·L-1)作用于HepG2细胞24 h后,采用MTT法检测细胞存活率,用Rhodamine123标记流式细胞术检测线粒体膜电位变化.结果:TEM结果显示,纳米SiO2颗粒呈球形,分散性好,大小均一.动态光散射法结果显示,纳米SiO2颗粒在无血清DMEM中粒径约为94 nm,分散性较好.纳米SiO2颗粒作用于HepG2细胞3 h即可进入细胞;作用24 h后,可以单一颗粒或成簇的形态分散在胞质内,并在线粒体等细胞器内沉积;不同浓度纳米SiO2颗粒作用于细胞24 h后,各组细胞存活率及线粒体膜电位较对照组均有显著下降(P＜0.05),且随着剂量增加细胞存活率和线粒体膜电位降低.结论:纳米SiO2颗粒进入细胞并在细胞器中沉积,可导致线粒体等细胞器的损伤,进而产生细胞毒性作用,抑制细胞增殖.     

葛根总黄酮诱导白血病细胞株凋亡及其分子机制的研究

目的 探讨葛根总黄酮(PR)对慢性粒细胞白血病(CML)细胞株K562和急性早幼粒细胞白血病(APL)细胞株NB4细胞增殖及凋亡的影响.方法 采用MTT法检测PR对K562细胞、NB4细胞的增殖抑制率;光学显微镜及荧光显微镜观察细胞形态改变;Hoechest33258荧光染色AnnexinV/PI双染法检测细胞凋亡率;DNA PI染色法分析细胞周期及亚二倍体峰.Western blot分别检测NB4细胞JNK、PARP、bcl-2、Caspase3,K562细胞bcr-abl、p53、bcl-2、Fas/FasL蛋白表达的变化.结果 12.5～200 μg/ml PR均能抑制K562、NB4细胞增殖.光学显微镜及荧光显微镜下观察到核固缩、凋亡小体等典型的细胞凋亡改变;Annexin V+/PI-细胞呈时间-剂量依赖性增加;DNA PI染色法发现细胞亚二倍体比例增加,G1期比例下降、S期比例增加.PR呈时间-剂量依赖性抑制K562细胞、NB4细胞增殖,诱导细胞凋亡.不同浓度PR干预后K562细胞bcr-abl蛋白水平呈浓度依赖性下调(F=18.74,P<0.05),而bcl-2则无明显变化;p53表达呈浓度依赖性上调;Fas/FasL表达无明显变化.NB4细胞JNK、PARP及Caspase 3蛋白表达与PR浓度呈正相关,与凋亡抑制蛋白bcl-2则呈负相关(F=42.32,P<0.05).结论 PR能有效抑制K562、NB4细胞增殖,阻滞细胞周期进程,诱导细胞凋亡,但分子机制不同.提示一定浓度PR具有较广谱的抗白血病效应.     

糖尿病大鼠阴茎海绵体线粒体氧化应激损伤与保护

目的:观察糖尿病大鼠阴茎海绵体线粒体氧化应激损伤变化和还原型谷胱甘肽(reduced glutathione,GSH)对其氧化损伤的影响,探讨阴茎海绵体氧化应激的保护机制以及氧化应激在糖尿病勃起功能障碍发病机制中的作用.方法:成年雄性SD大鼠42只,随机取32只予以腹腔注射大剂量链脲佐菌素(streptozotocin,STZ),建成糖尿病大鼠模型25只,随机分为糖尿病组(n=13)、还原型谷胱甘肽治疗组(n=12),另10只设为正常对照组;饲养8周后用电刺激各组大鼠勃起神经测定海绵体内压评价勃起功能;采用黄嘌呤氧化酶法检测阴茎海绵体组织中超氧化物氧化酶(superoxide dismutase,SOD)活性,硫代巴比妥酸法测丙二醛(malondialdehyde,MDA)含量;光镜下观察Masson染色切片;Emaus法检测线粒体膜电位.结果:糖尿病组较正常对照组,阴茎海绵体MDA含量显著增高[(6.15±1.07)vs.(3.52±0.94)nmol/mg蛋白,P＜0.01],SOD活性显著下降[(73.34±6.56)vs.(114.22±6.34)U/mg蛋白,P＜0.05],海绵体内压(intracavernous pressure,ICP)峰值显著降低[(50.80±9.80)vs.(90.42±7.02)mmHg,P＜0.05];GSH可使海绵体MDA含量明显降低[(3.90±0.96)vs.(6.15±1.07)nmol/mg蛋白,P＜0.05],显著提高其SOD值[(95.74±4.65)vs.(73.34±6.56)U/mg蛋白,P＜0.05]及ICP值[(74.20±5.69)vs.(50.80±9.80)mmHg,P＜0.05].糖尿病组大鼠阴茎组织中细胞线粒体膜电位减低[(727.98±68.33)vs.(1 223.15±222.92),P＜0.01],而GSH则能提高线粒体膜电位[(930.30±48.36)vs.(727.98±68.33),P＜0.05].结论:糖尿病大鼠阴茎海绵体存在氧化应激损伤,抗氧化治疗起着保护阴茎组织细胞线粒体功能的作用,从而减轻勃起组织的氧化应激损伤,提高勃起能力;氧化应激在糖尿病性勃起功能障碍发病过程中起到了重要作用.     

氯化铈对K562肿瘤细胞凋亡影响的实验研究

为了探讨氯化铈对肿瘤细胞凋亡的影响,本实验以K562细胞为研究对象,采用荧光显微镜定性检测细胞凋亡、流式细胞术定量测定细胞凋亡率.实验得出,与对照组相比,3mg/L氯化铈作用24h和500 mg/L氯化铈作用48h可以显著诱导细胞凋亡,30mg/L,150mg/L和250mg/L作用24h细胞凋亡率明显减少,同时氯化铈对K562细胞凋亡的影响随着作用时间的延长作用逐渐消失,对于同一时间来讲,氯化铈剂量和细胞凋亡之间的剂量-效应关系不明显.     

环氧合酶-2抑制剂对白血病细胞HL-60的化疗增敏作用及机制

目的 观察环氧合酶-2(COX-2)抑制剂塞来昔布对白血病细胞株HL-60的化疗增敏作用,并对其机制进行初步探讨.方法 MTT法评估塞来昔布、多柔比星及二者联合对HL-60细胞的生长抑制效应;流式细胞术(FCM)检测细胞的凋亡;反转录聚合酶链反应(RT-PCR)检测Survivin基因的表达;Western blotting检测Survivin蛋白的表达.结果 多柔比星联合塞来昔布5和10μmol/L对HL-60细胞的半数抑制浓度(IC50)分别为0.25及0.16μg/ml,明显低于多柔比星单用的IC50(0.48μg/ml);多柔比星0.10μg/ml联合10 μmol/L塞来昔布下调Survivin基因mRNA及蛋白的表达;联合塞来昔布5和10 μmol/L的凋亡率[分别为(13.07±1.66)%及(22.36±1.84)%]较多柔比星0.10μg/ml单用[(5.72±1.25)%]明显增加(P<0.01).结论 COX-2抑制剂塞来昔布对白血病细胞株HL-60具有明显的化疗增敏作用,其初步机制涉及下调Survivin的表达,增加细胞凋亡.     

Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3

Bcr-Abl expression in leukemic cells is known to exert a potent effect against apoptosis due to antileukemic drugs, but its mechanism has not been elucidated. Recent reports have indicated that a variety of apoptotic stimuli cause the preapoptotic mitochondrial release of cytochrome c (cyt c) into cytosol, which mediates the cleavage and activity of caspase-3 involved in the execution of apoptosis. Whether Bcr-Abl exerts its antiapoptotic effect upstream to the cleavage and activation of caspase-3 or acts downstream by blocking the ensuing degradation of substrates resulting in apoptosis, has been the focus of the present studies. In these, we used (1) the human acute myelogenous leukemia (AML) HL-60 cells that are stably transfected with the bcr-abl gene (HL-60/Bcr-Abl) and express p185 Bcr-Abl; and (2) the chronic myelogenous leukemia (CML)-blast crisis K562 cells, which have endogenous expression of p210 Bcr-Abl. Exposure of the control AML HL-60 cells to high-dose Ara-C (HIDAC), etoposide, or sphingoid bases (including C2 ceramide, sphingosine, or sphinganine) caused the accumulation of cyt c in the cytosol, loss of mitochondrial membrane potential (MMP), and increase in the reactive oxygen species (ROS). These preapoptotic events were associated with the cleavage and activity of caspase-3, resulting in the degradation of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) and DNA fragmentation factor (DFF), internucleosomal DNA fragmentation, and morphologic features of apoptosis. In contrast, in HL-60/Bcr-Abl and K562 cells, these apoptotic stimuli failed to cause the cytosolic accumulation of cyt c and other associated mitochondrial perturbations, as well as the failure to induce the activation of caspase-3 and apoptosis. While the control HL-60 cells showed high levels of Bcl-2 and barely detectable Bcl-xL, HL-60/Bcr-Abl cells expressed high levels of Bcl-xL and undetectable levels of Bcl-2, a pattern of expression similar to the one in K562 cells. Bax and caspase-3 expressions were not significantly different between HL-60/Bcr-Abl or K562 versus HL-60 cells. These findings indicate that Bcr-Abl expression blocks apoptosis due to diverse apoptotic stimuli upstream by preventing the cytosolic accumulation of cyt c and other preapoptotic mitochondrial perturbations, thereby inhibiting the activation of caspase-3 and execution of apoptosis.     

Temporal relationship of CDK1 activation and mitotic arrest to cytosolic accumulation of cytochrome C and caspase-3 activity during Taxol-induced apoptosis of human AML HL-60 cells

The antimicrotubule anticancer drug, Taxol, suppresses microtubule dynamics, causes mitotic arrest, and induces caspase-3 cleavage and activity resulting in apoptosis of human AML HL-60 cells. Caspase-3 cleavage is triggered by the mitochondrial release and cytosolic accumulation of the electron transfer protein, cytochrome c (cyt c). Taxol-induced G2/M transition is mediated by p34(cdc-2) (CDK1) which, if prematurely activated, may also trigger apoptosis. In the present studies following S-phase synchronization and release, HL-60 cells with enforced expression of the bcl-xL (HL-60/Bcl-xL) and/or neomycin resistance gene (HL-60/neo) were exposed to Taxol to examine CDK1-related cell-cycle events and the cyt c-triggered molecular cascade of apoptosis. At various time-intervals after Taxol treatment, immunoblot analyses of cyclin B1 and CDK1 levels were performed. In addition, the in vitro histone H1 kinase activity of immunoprecipitated CDK1 and its tyrosine phosphorylation status (by anti-phosphotyrosine immunoblot analysis) were determined. Data presented here show that, while Taxol-induced peak CDK1 kinase activity occurs earlier in HL-60/neo cells, there are no significant differences in cyclin B1 accumulation, tyrosine dephosphorylation of CDK1, and mitotic arrest of Taxol-treated HL-60/neo vs HL-60/Bcl-xL cells. Taxol-induced CDK1 activation and mitosis preceded the cytosolic accumulation (approximately six-fold) of cyt c. The latter event was blocked by Bcl-xL overexpression but not by inhibitors of caspase-3. Although the caspase inhibitors and high Bcl-xL levels inhibited caspase-3 cleavage and activity, they did not significantly affect Taxol-induced CDK1 activation or mitotic arrest. These findings indicate that Bcl-xL overexpression does not affect Taxol-induced CDK1 activity leading to G2/M transition, which temporally precedes the cytosolic cyt c-mediated cleavage and activity of caspase-3 and apoptosis.     

Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells

Recent studies have demonstrated that Apaf-1 is the adaptor molecule which in the presence of cytosolic cytochrome c (cyt c) and dATP interacts with procaspase-9, resulting in the sequential cleavage and activity of caspase-9 and caspase-3, followed by apoptosis. In the present studies, we determined the effect of enforced overexpression of Apaf-1 on the apoptotic threshold in the human myeloid leukemia HL-60 cells. Our findings demonstrate that both transient and stable transfections resulted in a 2.5-fold higher expression of Apaf-1, which was associated with approximately a 5-fold increase in the percentage of apoptosis in the transfectants (HL-60/Apaf-1) as compared with the control HL-60/neo cells. In cells overexpressing either Bcl-2 or Bcl-xL, transient overexpression of Apaf-1 did not induce apoptosis. Stably overexpressing Apaf-1 levels significantly sensitized HL-60/Apaf-1 cells to apoptosis induced by clinically achievable concentrations of paclitaxel or etoposide (P < 0.01). This increase in paclitaxel- or etoposide-induced apoptosis of HL-60/Apaf-1 cells was not associated with any significant alterations in Bcl-2, Bcl-xL, Bax, Fas, or Fas ligand expression. It was, however, clearly associated with caspase-9 cleavage, as well as the poly(ADP-ribose) polymerase and DFF45 cleavage activity of caspase-3. Coexpression of the catalytically inactive, dominant-negative, mutant caspase-9, XIAP, or treatment with the caspase inhibitor, zVAD, significantly inhibited the increase in apoptosis of HL-60/Apaf-1 cells (P < 0.01). These data indicate that the intracellular levels of Apaf-1 is an important molecular determinant of the threshold for apoptosis induced by paclitaxel and etoposide.     

A monocyte chemotactic factor, S19 ribosomal protein dimer, in phagocytic clearance of apoptotic cells

HL-60 cells derived from a human promyelocytic leukemia underwent apoptosis by heat treatment. When the heat-treated HL-60 cells were injected into guinea pig skin, monocyte/macrophage infiltration was observed 24 or 36 hours later, and the apoptotic cells were phagocytically cleared by 48 hours after their injection. The infiltration and clearance patterns were quite different from those observed in injection of necrotic or boil-fixed HL-60 cells. The apoptotic cells released a monocyte chemotactic factor in vitro 24 hours after the heat treatment. The chemotactic factor generated was identified as the cross-linked homodimer of S19 ribosomal protein by its immunologic and physicochemical properties. A serine protease that inactivates the monocyte chemotactic factor was also released from the apoptotic cells 30 hours after the heat treatment. A super infusion of this protease into the skin where the apoptotic cells had been injected diminished the number of infiltrated monocytes. The present results indicate an important role of the S19 ribosomal protein dimer in the phagocytic clearance of apoptotic cells.     

青蒿琥酯对急性单核细胞白血病SHI-1细胞株血管内皮生长因子及其受体表达的影响

目的 研究青蒿琥酯对急性单核细胞白血病SHI-1细胞株血管内皮生长因子(VEGF)及其受体( VEGFR)的影响。方法酶联免疫吸附法检测非细胞毒性浓度(5、10、20 ng/ml)青蒿琥酯作用SHI-1细胞后培养上清液VEGF浓度,流式细胞术检测有或无青蒿琥酯作用时,SHI-1细胞表面VEGFR-1及VEGFR-2阳性表达率。结果培养24、48 h后,无青蒿琥酯作用的SHI-1细胞培养上清液VEGF质量浓度分别为( 980.3±2.2)、(982.4±2.3) pg/ml,VEGFR-1表达率分别为(5.40±3.11)％和(4.45±2.85)％,VEGFR-2表达率分别为(13.90.± 2.26)％和（13.95±1.96）％。5、10、20 ng/ml青蒿琥酯作用24h后,SHI-1细胞培养上清液VEGF质量浓度分别为(234.6±1.8)、(114.9±1.6)、(108.8±1.5) pg/ml,作用48 h后分别为(62.3±1.7)、(60.9±1.6)、(32.7±1.7) pg/ml,与培养相同时间无青蒿琥酯组相比,VEGF浓度明显下降（均P＜ 0.05）,且相同浓度青蒿琥酯作用24 h与48 h间差异亦有统计学意义(均P＜ 0.05)。5、10、20 ng/ml青蒿琥酯作用24 h,VEGFR-1阳性率分别为(4.30±2.21)％、(4.20±1.37)％和(3.90±1.86)％,作用48 h后分别为(3.80±2.87)％、(3.60±1.73)％和(3.00±1.82)％,相同作用时间不同浓度青蒿琥酯组间及相同浓度作用不同时间组间VEGFR-1阳性率差异均无统计学意义(均P＞ 0.05);作用24h后,SHI-1细胞VEGFR-2阳性率分别为(4.40±1.15)％、(3.10±0.68)％和(1.10±0.72)％,作用48 h后分别为(3.00±1.68)％、(2.20±0.93)％和(0.60±0.92)％,3个不同浓度青蒿琥酯作用相同时间后VEGFR-2表达率降低（均P＜ 0.05）,相同浓度作用24与48 h间差异均无统计学意义（均P＞ 0.05）。结论SHI-1细胞株高分泌VEGF,青蒿琥酯可下调VEGF分泌及VEGFR-2的表达,而对VEGFR-1表达的调节作用不显著。     

明日叶查尔酮对小鼠肝癌细胞凋亡相关蛋白表达的影响

Objective: The aim of our study was to investigate the effect of Angelica keiskei chalcone (AC) on the expression of Caspase-3 and Bax in mice hepatocarcinoma cells. Methods: Fifty mice inoculated hepatocarcinoma 22 cells were divided into five groups, 10 mice per group. Mice were given 5, 20, 40 mg/kg AC daily by mouth in low, middle and high dose groups respectively. Saline were given to the tumor control group by mouth. Twenty mg/kg cytoxan (CTX) by injection every other day were given to the positive control group. Ten days later, all mice were sacrificed. The levels of the Caspase-3 and Bax protein expression were measured by immunohistochemistry method and the proliferation activity of hepatocarcinoma cells was determined by MTT assay. Results: The expression level of Caspase-3 and Bax protein in tumor control group were 5.00%and 4.68%, respectively, and those of the high-dose group were 38.52% and 35.76%. The differences between two groups were significant (P ＜ 0.05). The cell proliferation activity of tumor control group and high-dose group were 1.135 ± 0.032 and 0.716 ± 0.018. The difference was significant (P ＜ 0.05). Conclusion:AC can increase the expression of Caspase-3 and Bax protein, and inhibit the proliferative activity of mice hepatocarcinoma cells.